Thermo Fisher Scientific (TMO)
(Delayed Data from NYSE)
$596.92 USD
+3.13 (0.53%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $596.52 -0.40 (-0.07%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$596.92 USD
+3.13 (0.53%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $596.52 -0.40 (-0.07%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
Zacks News
Top Analyst Reports for Boeing, Thermo Fisher & Anthem
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Boeing (BA), Thermo Fisher (TMO) and Anthem (ANTM).
Thermo Fisher (TMO) Beats on Earnings and Revenues in Q4
by Zacks Equity Research
Thermo Fisher (TMO) gains on growth in all business segments in Q4.
Thermo Fisher Scientific (TMO) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Thermo Fisher (TMO) delivered earnings and revenue surprises of 1.88% and 4.32%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Thermo Fisher (TMO) Down on Business Divestment Declaration
by Zacks Equity Research
Thermo Fisher's (TMO) Anatomical Pathology business comes under its Specialty Diagnostics segment catering to customers at healthcare and clinical laboratories.
Will Overall Growth Aid Thermo Fisher's (TMO) Q4 Earnings?
by Zacks Equity Research
Thermo Fisher (TMO) rides high on a steadily strong analytical instrument business, flaunting robust global demand.
Thermo Fisher Scientific (TMO) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Thermo Fisher (TMO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Thermo Fisher (TMO) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Thermo Fisher (TMO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Has Thermo Fisher Scientific (TMO) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (TMO) Outperforming Other Medical Stocks This Year?
The Zacks Analyst Blog Highlights: Eli Lilly, Mitsubishi UFJ, Thermo Fisher, Oracle and Ecolab
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Eli Lilly, Mitsubishi UFJ, Thermo Fisher, Oracle and Ecolab
Top Analyst Reports for Eli Lilly, Mitsubishi UFJ & Thermo Fisher
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), Mitsubishi UFJ Financial Group, Inc. (MUFG) and Thermo Fisher Scientific Inc. (TMO).
Thermo Fisher (TMO) Rides on New Buyouts and APAC Strength
by Zacks Equity Research
We are upbeat about Thermo Fisher's (TMO) recent buyout of Advanced Bioprocessing business, which will add complementary cell culture products to the company's bioproduction suit.
Has Thermo Fisher Scientific (TMO) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (TMO) Outperforming Other Medical Stocks This Year?
Zacks.com featured highlights include: Intel, Thermo Fisher, Marcus, Anthem and ArcBest
by Zacks Equity Research
Zacks.com featured highlights include: Intel, Thermo Fisher, Marcus, Anthem and ArcBest
The Zacks Analyst Blog Highlights: Alphabet, Bank of America, Tesla, Thermo Fisher and Carnival
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Alphabet, Bank of America, Tesla, Thermo Fisher and Carnival
5 Solid Dividend Growth Stocks for Your Portfolio
by Sweta Killa
Dividend-paying securities are the major source of consistent income for investors when returns from the equity market are at risk.
Top Analyst Reports for Alphabet, Bank of America & Tesla
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Alphabet (GOOGL), Bank of America (BAC) and Tesla (TSLA).
The Zacks Analyst Blog Highlights: Johnson & Johnson, Thermo Fisher, Goldman Sachs, Oracle and Accenture
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson & Johnson, Thermo Fisher, Goldman Sachs, Oracle and Accenture
Here's Why You Should Buy Thermo Fisher (TMO) Stock Now
by Zacks Equity Research
Thermo Fisher (TMO) gains on strength in all end markets. It witnesses consistent growth in the Asia-Pacific and emerging markets.
Top Analyst Reports for Johnson & Johnson, Thermo Fisher & Goldman Sachs
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), Thermo Fisher (TMO) and Goldman Sachs (GS).
Thermo Fisher (TMO) Rides on APAC Strength Despite Cost Woes
by Zacks Equity Research
Thermo Fisher (TMO) is registering a sturdy global footprint with strong growth seen in Asia-Pacific including China.
Is Thermo Fisher Scientific (TMO) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (TMO) Outperforming Other Medical Stocks This Year?
Pacific Biosciences Offers Insights on Aedes aegypti Genome
by Zacks Equity Research
Pacific Biosciences (PACB) uses its flagship Single Molecule, Real-Time technology to sequence the highest quality genome assembly for the Aedes aegypti mosquito.
Pacific Biosciences (PACB) Reports Q3 Loss, Revenues Fall Y/Y
by Zacks Equity Research
Pacific Biosciences (PACB) is getting acquired by Illumina (ILMN) by mid-2019.
Illumina (ILMN) Inks $1.2B Deal to Buy Pacific Biosciences
by Zacks Equity Research
Illumina (ILMN) taking out on its peer, in the $1.2-billion acquisition deal, will further strengthen the position of the former in the genomics market.
Zacks.com highlights: Dick's Sporting Goods, Microsoft, Matson, Thermo Fisher Scientific and Progressive
by Zacks Equity Research
Zacks.com highlights: Dick's Sporting Goods, Microsoft, Matson, Thermo Fisher Scientific and Progressive